不同方案治疗新生儿病理性黄疸的疗效与药物经济学比较  

Comparison of therapeutic effects and pharmacoeconomics of different regimens in the treatment of neonatal pathological jaundice

作　　者：陶丽君[1] 王云飞 王健[1] 姚瑛[1] 陈雯[1] TAO Li-jun;WANG Yun-fei;WANG Jian(The People's Hospital of Ningxia Hui Autonomous Region(The First Affiliated Hospital of Northwest University for Nationalities),Yinchuan 750021,China;不详)

机构地区：[1]宁夏回族自治区人民医院(西北民族大学第一附属医院),银川750021 [2]银川市第二人民医院,银川750011

出　　处：《中国处方药》2023年第5期1-5,共5页Journal of China Prescription Drug

基　　金：宁夏回族自治区科技惠民专项项目(2019CMG03008)。

摘　　要：目的比较不同方案治疗新生儿病理性黄疸的临床疗效与安全性,并进行药物经济学评价。方法回顾性分析某医院2019年1月~2020年12月收治的新生儿病理性黄疸患儿治疗方案,依据不同治疗方案进行分组。通过比较各组患儿治疗前后胆红素水平和治疗后不良反应发生情况,对治疗方案的临床疗效与安全性进行比较,同时从经济角度评价、分析各治疗方案的成本-效果比。结果与对照组比较,双歧三联活菌胶囊组辅助降低总胆红素、未结合胆红素(TBil、IBil)指标无显著优势(P>0.05);枯草杆菌二联活菌肠溶胶囊组在治疗前TBil、IBil指标显著高于对照组和双歧三联活菌胶囊组的情况下(P<0.05),经相同疗程后各组指标下降至相同水平(P>0.05);治疗前枯草杆菌二联活菌肠溶胶囊+人血白蛋白组TBil、IBil指标显著高于枯草杆菌二联活菌肠溶胶囊组(P<0.05),经相同疗程后两组指标下降至相同水平(P>0.05);与对照组比较,各组治愈率结果无差别(P>0.05);各组在治疗期间均未出现药物不良反应;双歧三联活菌胶囊组成本显著高于对照组和枯草杆菌二联活菌肠溶胶囊组(P<0.05),三组成本-效果比差异也具有统计学意义(P<0.05);枯草杆菌二联活菌肠溶胶囊+人血白蛋白组成本相比枯草杆菌二联活菌肠溶胶囊组显著增高(P<0.05),成本-效果比差异也具有统计学意义(P<0.05)。结论枯草杆菌二联活菌肠溶胶囊辅助治疗新生儿黄疸的有效性、成本-效果比均优于双歧三联活菌胶囊,且安全性良好。人血白蛋白在降低胆红素指标方面具有显著疗效,但治疗成本较高。Objective To compare the clinical efficacy and safety of different regimens in the treatment of neonatal pathological jaundice,and to evaluate pharmacoeconomics.Methods Retrospective analysis was performed on the treatment regimens of neonatal pathological jaundice admitted to a hospital from January 2019 to December 2020 and the treatment regimens were grouped according to different treatment regimens.By comparing the bilirubin levels before and after treatment and adverse reactions after treatment in each group,the clinical efficacy and safety of treatment programs were compared,and the cost-effectiveness ratio of each treatment program was evaluated and analyzed from an economic perspective.Results Compared with the control group,there was no significant advantage in the auxiliary reduction of TBil,IBil indicators in the bifid triple viable bacteria capsules group(P>0.05).Before treatment,the TBil,IBil index of the live combined bacillus subtilis and enterococcus faecium enteric-coated capsules group was significantly higher than that of the control group and the bifid triple viable bacteria capsules group(P<0.05).After the same course of treatment,the indicators of each group decreased to the same level(P>0.05).Before treatment,the TBil,IBil index of the live combined bacillus subtilis and enterococcus faecium enteric-coated capsules+human serum albumin group was significantly higher than that of the live combined bacillus subtilis and enterococcus faecium enteric-coated capsules group(P<0.05),and the index of the two groups decreased to the same level after the same course of treatment(P>0.05).There was no difference in cure rate among the groups(P>0.05).No adverse drug reactions occurred in each group during the treatment.The cost of bifid triple viable bacteria capsules was significantly higher than that of control group and live combined bacillus subtilis and enterococcus faecium enteric-coated capsules group(P<0.05),and the difference of cost-effectiveness ratio of the three components was also statistic

关 键 词：双歧三联活菌胶囊 枯草杆菌二联活菌肠溶胶囊 人血白蛋白 胆红素 成本-效果比 

分 类 号：R722.17[医药卫生—儿科] R956[医药卫生—临床医学]